JP2023516615A5 - - Google Patents

Info

Publication number
JP2023516615A5
JP2023516615A5 JP2022551667A JP2022551667A JP2023516615A5 JP 2023516615 A5 JP2023516615 A5 JP 2023516615A5 JP 2022551667 A JP2022551667 A JP 2022551667A JP 2022551667 A JP2022551667 A JP 2022551667A JP 2023516615 A5 JP2023516615 A5 JP 2023516615A5
Authority
JP
Japan
Application number
JP2022551667A
Other languages
Japanese (ja)
Other versions
JP2023516615A (ja
JPWO2021170838A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/054911 external-priority patent/WO2021170838A1/en
Publication of JP2023516615A publication Critical patent/JP2023516615A/ja
Publication of JP2023516615A5 publication Critical patent/JP2023516615A5/ja
Publication of JPWO2021170838A5 publication Critical patent/JPWO2021170838A5/ja
Priority to JP2025179567A priority Critical patent/JP2026035582A/ja
Pending legal-status Critical Current

Links

JP2022551667A 2020-02-27 2021-02-26 ショックを患っている患者におけるnt-adm抗体治療法ガイダンス、モニタリング、及び層別化のためのdpp3 Pending JP2023516615A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025179567A JP2026035582A (ja) 2020-02-27 2025-10-24 ショックを患っている患者におけるnt-adm抗体治療法ガイダンス、モニタリング、及び層別化のためのdpp3

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20159848 2020-02-27
EP20159848.9 2020-02-27
PCT/EP2021/054911 WO2021170838A1 (en) 2020-02-27 2021-02-26 Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025179567A Division JP2026035582A (ja) 2020-02-27 2025-10-24 ショックを患っている患者におけるnt-adm抗体治療法ガイダンス、モニタリング、及び層別化のためのdpp3

Publications (3)

Publication Number Publication Date
JP2023516615A JP2023516615A (ja) 2023-04-20
JP2023516615A5 true JP2023516615A5 (https=) 2024-02-29
JPWO2021170838A5 JPWO2021170838A5 (https=) 2024-02-29

Family

ID=69742802

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022551667A Pending JP2023516615A (ja) 2020-02-27 2021-02-26 ショックを患っている患者におけるnt-adm抗体治療法ガイダンス、モニタリング、及び層別化のためのdpp3
JP2025179567A Pending JP2026035582A (ja) 2020-02-27 2025-10-24 ショックを患っている患者におけるnt-adm抗体治療法ガイダンス、モニタリング、及び層別化のためのdpp3

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025179567A Pending JP2026035582A (ja) 2020-02-27 2025-10-24 ショックを患っている患者におけるnt-adm抗体治療法ガイダンス、モニタリング、及び層別化のためのdpp3

Country Status (9)

Country Link
US (1) US20230193348A1 (https=)
EP (1) EP4111204A1 (https=)
JP (2) JP2023516615A (https=)
CN (1) CN115244401A (https=)
AU (1) AU2021228207A1 (https=)
BR (1) BR112022015215A2 (https=)
CA (1) CA3172349A1 (https=)
MX (1) MX2022010672A (https=)
WO (1) WO2021170838A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010564A (es) * 2020-02-27 2022-11-30 Adrenomed Ag Aglutinante anti-adrenomedulina (adm) para usarse en terapia de pacientes en choque.
KR20250042158A (ko) 2022-07-29 2025-03-26 아드레노메드 아게 쇼크의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드
CN119630969A (zh) 2022-07-29 2025-03-14 4Teen4制药有限公司 预测患有败血症性休克的患者中的dpp3增加
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
RU2004109222A (ru) 2001-08-30 2005-10-20 Байорексис Фармасьютикал Корпорейшн (Us) Слитые белки модифицированного трансферрина
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
EP1620734A1 (en) 2003-04-25 2006-02-01 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20070280886A1 (en) 2004-09-09 2007-12-06 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
AU2010332932B2 (en) 2009-12-14 2013-01-17 Navigo Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
RU2569745C2 (ru) 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
PL2594588T3 (pl) 2011-11-16 2014-11-28 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii
EP2780370B1 (en) 2011-11-16 2019-09-25 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
SG11201402362VA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
DK2780371T3 (en) 2011-11-16 2019-02-25 Adrenomed Ag ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE
EP4086283A1 (en) 2011-11-16 2022-11-09 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
AU2017252212B2 (en) * 2016-04-21 2023-09-07 4TEEN4 Pharmaceuticals GmbH Methods for determining DPP3 and therapeutic methods
SG11202002268XA (en) * 2017-10-18 2020-04-29 Adrenomed Ag Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
MY202502A (en) * 2017-10-25 2024-05-01 4TEEN4 Pharmaceuticals GmbH Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JP2023516615A5 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)